乳腺浸润性导管癌组织Ki-67表达及其临床病理学意义

Expression and Clinical Pathological Significance of Ki-76 in Breast Invasive Ductal Carcinoma

目的探讨Ki-67增殖抗原在乳腺浸润性导管癌组织中的表达情况及其与临床病理学特征之间的关系。方法选取76例行乳腺癌根治术患者的临床资料及其组织标本,采用免疫组织化学SP法检测乳腺浸润性导管癌组织中Ki-67的表达,并分析其与乳腺浸润性导管癌结合病理特点及分子分型的相关性。结果乳腺浸润性导管癌组织Ki-67的阳性表达率为81.58%(62/76),不同分子分型中,IuminalA型Ki-67阳性表达率最低,为7.69%(1/13),三阴性阳性表达率最高,为100.00%(15/15)。Ki-67蛋白阳性表达与肿瘤直径(2=10.081,P=0.006)、淋巴结转移情况(2=11.878,P=0.001)、TNM分期(2=19.465,P<0.001)和组织学分级(2=9.268,P=0.010)明显相关。Ki-67表达与雌激素受体(ER)(r=-0.245,P=0.033)、孕激素受体(PR)(r=-0.395,P=0.001)表达水平呈负相关,与p53(r=0.613,P<0.001)、CerbB-2(r=0.270,P=0.018)呈正相关。结论 Ki-67在乳腺浸润性导管癌中高表达,与患者临床病理参数相关,Ki-67在乳腺浸润性导管癌患者的诊断和预后评估中具有较高的参考价值。

Objective To investigate the expression and clinicopathological significance of Ki-67 in breast infiltrative ductal carcinoma（IDC）.Methods The clinical data and tissue samples of 76 breast IDC patients undergoing radical mastectomy were collected.Immunohisto-chemical SP method was applied to detect the expression of Ki-67 from carcinoma tissues of 76 cases.The association of expression of Ki-63 with pathological character and molecular classification was analyzed statistically.Results The positive expression percentage of Ki-67 was 81.58%（62/76）in carcinoma tissue.The positive expression percentage was lowest in Iuminal A type[7.69%（1/13）]and was highest in triple negative type[100.00%（15/15）].The positive expression of Ki-67 was associated with tumor size（X^2=10.081,P=0.006）,lymphatic metastasis（X^2=11.878,P=0.001）,TNM staging（X^2=19.465,P〈0.001）and histological grading（X^2=9.268,P=0.010）.Expression of Ki-67 was negatively correlated with ER（r=-0.245,P=0.033）and PR（r=-0.395,P=0.001）levels,and was positively correlated with p53（r=0.613,P〈0.001）and CerbB-2（r=0.270,P=0.018）levels.Conclusion Findings indicate a closed relationship between high expression of Ki-67 and clinical pathological parameters,which is potentially useful in IDC prognosis prediction.